Stockscreener 앱 받기
0.9664
3.96%
-0.0436
전일 마감가:
$1.01
열려 있는:
$1.09
하루 거래량:
4.81M
Relative Volume:
4.34
시가총액:
$10.57M
수익:
$2.05M
순이익/손실:
$-23.15M
주가수익비율:
-0.1457
EPS:
-6.6319
순현금흐름:
$-16.93M
1주 성능:
-7.62%
1개월 성능:
-69.92%
6개월 성능:
-63.53%
1년 성능:
-51.26%
1일 변동 폭
$0.9401
$1.15
1주일 범위
$0.9401
$1.62
52주 변동 폭
$0.6358
$6.8908
iBio Inc Stock (IBIO) Company Profile
명칭
iBio Inc
전화
302-355-0650
주소
600 Madison Avenue, Suite 1601, New York, NY
IBIO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IBIO
iBio Inc
|
0.97 | 10.57M | 2.05M | -23.15M | -16.93M | -6.6319 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.74 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.25 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.38 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.21 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.28 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
iBio Inc Stock (IBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-05-28 | 개시 | Chardan Capital Markets | Buy |
| 2021-11-29 | 개시 | JMP Securities | Mkt Outperform |
| 2021-01-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-06-26 | 개시 | Alliance Global Partners | Buy |
iBio Inc 주식(IBIO)의 최신 뉴스
Chardan Capital Maintains Buy Rating for iBio (IBIO) with $5 Price Target | IBIO Stock News - GuruFocus
iBio (IBIO) Reports Promising Results from Activin E Antibody Study | IBIO Stock News - GuruFocus
iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model - The Manila Times
Revolutionary Obesity Treatment Achieves 77% Fat Reduction While Preserving Muscle Mass, Outperforms GLP-1s - Stock Titan
iBio, Inc. Reports Strong Q3 2025 Progress - TipRanks
iBio, Inc. (NYSE:IBIO) Shares Purchased by Geode Capital Management LLC - Defense World
iBio, Inc. (NYSEAMERICAN:IBIO) Short Interest Down 20.9% in April - Defense World
IBio Reports Fiscal Third Quarter 2025 Financial Results - marketscreener.com
iBio (IBIO) Secures Financial Growth and Advances Drug Pipeline - GuruFocus
iBio Reports Fiscal Third Quarter 2025 Financial Results | IBIO Stock News - GuruFocus
iBio, Inc. Reports Q3 2025 Financial Results and Corporate Progress Following Nasdaq Listing - Nasdaq
iBio Reports Strong Pipeline Data and Nasdaq Uplisting as Q3 R&D Investment Doubles - Stock Titan
Take off with iBio Inc (IBIO): Get ready for trading - Sete News
Analyzing iBio Inc (IBIO) After Recent Trading Activity - knoxdaily.com
iBio Raises $6.2 Million Through Warrant Inducement Transaction - GuruFocus
iBio Raises $6.2 Million Through Warrant Inducement Transaction | IBIO Stock News - GuruFocus
Biotech Firm iBio Raises $6.2M in Fresh Capital: New Warrants Issued at $0.86 - Stock Titan
What to expect from iBio Inc’s (IBIO) current quarter earnings? - uspostnews.com
Teck Resources Ltd [TECK] Insider Activity: An Update for Investors - knoxdaily.com
iBio (NYSE:IBIO) Trading Up 14.3% – Should You Buy? - Defense World
An Overview of iBio Inc (NASDAQ: IBIO)’s Stock Performance and Outlook - Marketing Sentinel
Analytical Overview: TMC the metals company Inc (TMC)’s Ratios Tell a Financial Story - DWinneX
Quarterly Snapshot: Quick and Current Ratios for iBio Inc (IBIO) - DWinneX
iBio - The Pharma Letter
AstralBio - The Pharma Letter
iBio Inc (IBIO) expanding its growth trajectory ahead - Sete News
Off-market insider buying at Tantalex Lithium Resource (TTX) - The Globe and Mail
Monitoring iBio Inc (IBIO) after recent insider movements - knoxdaily.com
In the Green: iBio Inc (IBIO) Closes at 0.70, Up/Down -17.43 from Previous Day - DWinneX
Ibio Inc Enters Exclusive License Agreement With AstralBio - marketscreener.com
iBio Enters Licensing Agreement for Obesity Treatment - TipRanks
iBio Inc (IBIO) Stock: Uncovering 52-Week Market Trends - investchronicle.com
Breaking down IBIO’s current quarter earnings estimates - uspostnews.com
iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio - The Manila Times
Revolutionary AI-Discovered Obesity Drug: iBio Licenses First-Ever Activin E Antibody in $28M Deal - Stock Titan
Porch Group Inc (PRCH) Stock: A Year of Stock Market Dynamics - investchronicle.com
iBio Stock Plummets Despite Positive Data On Weight-Loss Treatment Antibody: Retail Stays Bearish - MSN
iBio stock touches 52-week low at $1.03 amid market challenges By Investing.com - Investing.com South Africa
iBio stock touches 52-week low at $1.03 amid market challenges - Investing.com Australia
iBio (NYSEMKT:IBIO) Stock Price Down 5.5% – Here’s What Happened - Defense World
iBio Highlights Advancements in Obesity Antibody Programs - TipRanks
iBio Inc (NASDAQ: IBIO): Time To Buy Over The Next Few Months - Marketing Sentinel
iBio reports promising data on obesity treatment antibody By Investing.com - Investing.com South Africa
iBio reports promising data on obesity treatment antibody - Investing.com Australia
iBio stock touches 52-week low at $1.42 amid market challenges - Investing.com Australia
iBio stock touches 52-week low at $1.42 amid market challenges By Investing.com - Investing.com South Africa
Where Do Analysts Think The iBio Inc (NASDAQ: IBIO) Is Going - stocksregister.com
Ibio reports preclinical results for antibodies in cardiometabolic and obesity pipeline - BioWorld MedTech
Ibio IncOn Track For Regulatory Submission For Ibio-600 In Q1 2026 - MarketScreener
iBio Reveals Promising Study Results for IBIO-600 - TipRanks
iBio announces data from non-human primate PK study of IBIO-600 - TipRanks
iBio Inc (IBIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.52%
자본화:
|
볼륨(24시간):